Literature DB >> 23509157

β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis.

Thomas Oellerich1, Mark F Oellerich, Michael Engelke, Silvia Münch, Sebastian Mohr, Marika Nimz, He-Hsuan Hsiao, Jasmin Corso, Jing Zhang, Hanibal Bohnenberger, Tobias Berg, Michael A Rieger, Jürgen Wienands, Gesine Bug, Christian Brandts, Henning Urlaub, Hubert Serve.   

Abstract

Spleen tyrosine kinase (Syk) induces cell survival and proliferation in a high proportion of acute myeloid leukemia (AML) blasts, but the underlying molecular events of Syk signaling have not been investigated. Proteomic techniques have allowed us to identify the multiprotein complex that is nucleated by constitutively active Syk in AML cells. This complex differs from the B-lymphoid Syk interactome with respect to several proteins, especially the integrin receptor Mac-1, the Fc-γ receptor I (FcγRI), and the transcription factors STAT3 and STAT5. We show in several AML cell line models that tonic signals derived from the Fc-γ chain lead to Syk-dependent activation of STAT3 and STAT5, which in turn induces cell survival and proliferation. Moreover, stimulation of Mac-1 or FcγRI intensifies the constitutive Syk-mediated STAT3/5 activation in AML cells, a scenario likely to take place in the bone marrow niche. In accordance with these findings, we observed that β2 integrins, including Mac-1, trigger proliferation of AML cells in an AML cell/stroma coculture model. Taken together, we identified an oncogenic integrin/Syk/STAT3/5 signaling axis that might serve as a therapeutic target of AML in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509157     DOI: 10.1182/blood-2012-09-457887

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.

Authors:  Jessica Barth; Khalil Abou-El-Ardat; Denis Dalic; Nina Kurrle; Anna-Maria Maier; Sebastian Mohr; Judith Schütte; Lothar Vassen; Gabriele Greve; Johannes Schulz-Fincke; Martin Schmitt; Milica Tosic; Eric Metzger; Gesine Bug; Cyrus Khandanpour; Sebastian A Wagner; Michael Lübbert; Manfred Jung; Hubert Serve; Roland Schüle; Tobias Berg
Journal:  Leukemia       Date:  2019-01-24       Impact factor: 11.528

2.  Systems-Based Interactome Analysis for Hematopoiesis Effect of Angelicae sinensis Radix: Regulated Network of Cell Proliferation towards Hemopoiesis.

Authors:  Guang Zheng; He Zhang; Yun Yang; Ying-Li Sun; Yan-Jing Zhang; Ju-Ping Chen; Ting Hao; Cheng Lu; Hong-Tao Guo; Ge Zhang; Dan-Ping Fan; Xiao-Juan He; Ai-Ping Lu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

3.  Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.

Authors:  Jasmin Corso; Kuan-Ting Pan; Roland Walter; Carmen Doebele; Sebastian Mohr; Hanibal Bohnenberger; Philipp Ströbel; Christof Lenz; Mikolaj Slabicki; Jennifer Hüllein; Federico Comoglio; Michael A Rieger; Thorsten Zenz; Jürgen Wienands; Michael Engelke; Hubert Serve; Henning Urlaub; Thomas Oellerich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-06       Impact factor: 11.205

4.  Syk Is Recruited to Stress Granules and Promotes Their Clearance through Autophagy.

Authors:  Mariya O Krisenko; Reneé L Higgins; Soumitra Ghosh; Qing Zhou; Joy S Trybula; Wen-Horng Wang; Robert L Geahlen
Journal:  J Biol Chem       Date:  2015-10-01       Impact factor: 5.157

Review 5.  Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

Authors:  Mariya O Krisenko; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2014-11-04

6.  SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Authors:  Alexandre Puissant; Nina Fenouille; Gabriela Alexe; Yana Pikman; Christopher F Bassil; Swapnil Mehta; Jinyan Du; Julhash U Kazi; Frédéric Luciano; Lars Rönnstrand; Andrew L Kung; Jon C Aster; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Michael T Hemann; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Authors:  Daniel J Deangelo; Donna Neuberg; Philip C Amrein; Jacob Berchuck; Martha Wadleigh; L Andres Sirulnik; Ilene Galinsky; Todd Golub; Kimberly Stegmaier; Richard M Stone
Journal:  Leuk Res       Date:  2013-11-05       Impact factor: 3.156

Review 8.  STAT5 in hematopoietic stem cell biology and transplantation.

Authors:  Zhengqi Wang; Kevin D Bunting
Journal:  JAKSTAT       Date:  2013-11-19

9.  Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.

Authors:  Anjali Cremer; Jana M Ellegast; Gabriela Alexe; Elizabeth S Frank; Linda Ross; S Haihua Chu; Yana Pikman; Amanda Robichaud; Amy Goodale; Björn Häupl; Sebastian Mohr; Arati V Rao; Alison R Walker; James S Blachly; Federica Piccioni; Scott A Armstrong; John C Byrd; Thomas Oellerich; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2019-11-26       Impact factor: 38.272

10.  Automatic context-specific subnetwork discovery from large interaction networks.

Authors:  Ashis Saha; Aik Choon Tan; Jaewoo Kang
Journal:  PLoS One       Date:  2014-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.